Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Dissolution Qualification

By Drug Discovery Trends Editor | May 17, 2012

Agilent Technologies Inc. has introduced the 280-DS mechanical qualification system, an instrument designed for routine calibration of a dissolution apparatus. The 280-DS accurately measures, verifies and documents physical parameters established with recently enhanced mechanical qualification standards, eliminating the need for visual interpretation of measurements from manual gauges.

Dissolution is a technique used in the pharmaceutical industry to determine the rate at which active pharmaceutical ingredients release from solid dosage forms such as tablets and capsules. The 280-DS Mechanical Qualification System, with its 280-DS Workstation Software, redefines dissolution qualification with optical-sensing technology that delivers virtually hands-free measurements in seconds.

“Pharmaceutical customers now have one instrument that supports whichever type of qualification their dissolution laboratory requires,” said Allan Little, Agilent director of marketing for dissolution systems. “The 280-DS precisely measures the critical parameters required for qualification in a fraction of the time it used to take. Efficiency, time savings, accuracy, and documentation are all realized with this instrument.”

The 280-DS Mechanical Qualification System supports traditional and enhanced qualification methods to meet current Good Manufacturing Practices (cGMP). Whether the laboratory uses the U.S. Pharmacopeia’s Performance Verification Test (PVT) or the U.S. Food and Drug Administration and American Society for Testing and Materials (ASTM) Enhanced Mechanical Qualification standards, the 280-DS offers unprecedented measurement capabilities.

Agilent Technologies Inc. https://www.chem.agilent.com/en-US/Products/instruments/dissolution/calibrationtools/280-ds/pages/default.aspx


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50